Abstract: Alkylene oxides are polymerized in a tubular reactor. The alkylene oxide is continuously introduced into the tubular reactor through multiple introduction points located along the length of the tubular reactor. Monomer flow rates are increased along the length of the reactor to maintain a nearly constant concentration of unreacted alkylene oxide.

Abstract: Sound-permeable lining (1) for covering perforations (21) shaped in an acoustic plasterboard (2). The sound-permeable lining (1) comprises a first ply (12) of a fleece material and attached thereto a second ply (14) which is arranged in between of the first ply (12) and the acoustic plasterboard (2) to which the sound-permeable lining (1) is to be applied. The second ply (14) being of a foil material having a second opacity O2 and a plurality of through-holes (141) formed therein. The first ply (12) has a first opacity O1 so that the through-holes (141) formed in the second ply (14) are invisible through the first ply (12) and so that the applied sound-permeable lining (1) has an overall opacity O12 to allow for optically covering the perforations (21) shaped in the acoustic plasterboard (2) and an overall air flow resistivity Rs12 to allow for the penetration of air so that sound can propagate via the sound-permeable lining (1).

Abstract: Unsaturated polyether monols are removed from polyether polyols by reaction with a functionalized thiol compound or a polythiol compound. This process replaces the terminal unsaturation with a functional group, or else couples two or more of the monols to form a polyol. The functionality of the polyether polyol product is increased by the removal of the monols.

Abstract: Alkylene oxides are polymerized in a tubular reactor. The alkylene oxide is continuously introduced into the tubular reactor through multiple introduction points located along the length of the tubular reactor. Monomer flow rates are increased along the length of the reactor to maintain a nearly constant concentration of unreacted alkylene oxide.

Abstract: Embodiments relate to determining a speed of a multidimensional motion of an athlete in a global coordinate system based on multidimensional acceleration data from a multidimensional accelerometer placed at a movable limb of the athlete, the movable limb being at least one of translatory and rotatable, and the movable limb defining a local coordinate system. Based on the multidimensional acceleration data, at least one correction quantity may be determined taking into account a rotation of the local coordinate system relative to the global coordinate system during the multidimensional motion. The speed of the multidimensional motion may be determined based on an integration of the multidimensional acceleration data and in consideration of the at least one correction quantity.

Abstract: Vinyl-functional alcohols are silylated by reaction with a hydrolysable silyl hydride compound. The starting alcohol is heated and then combined with the silyl hydride and catalyst and allowed to heat exothermically. Cooling is applied when the conversion of vinyl groups is between 90-99%. In some embodiments, specified amounts of water are present. The cooling regimen and control of water content reduces certain side reactions, leading to greater yields to desired product.

Abstract: A method of producing a high primary hydroxyl group content and a high number average molecular weight polyol includes preparing a mixture that includes a double metal cyanide catalyst and a low molecular weight polyether polyol having a number average molecular weight of less than 1,000 g/mol, the polyether polyol is derived from propylene oxide, ethylene oxide, or butylene oxide, setting the mixture to having a first temperature, adding at least one selected from propylene oxide, ethylene oxide, and butylene oxide to the mixture at the first temperature, allowing the mixture to react to form a reacted mixture, adding a Lewis acid catalyst to the reacted mixture, setting the reaction mixture including the second catalyst to have a second temperature that is less than the first temperature, and adding additional at least one selected from propylene oxide, ethylene oxide, and butylene oxide to the reacted mixture at the second temperature such that a resultant polyol having a primary hydroxyl group content of

Abstract: Vinyl-functional alcohols are silylated by reaction with a hydrolysable silyl hydride compound. The starting alcohol is heated and then combined with the silyl hydride and catalyst and allowed to heat exothermically. Cooling is applied when the conversion of vinyl groups is between 90-99%. In some embodiments, specified amounts of water are present. The cooling regimen and control of water content reduces certain side reactions, leading to greater yields to desired product.

Abstract: {4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of AKI (acute kidney injury). Medicament and pharmaceutical composition thereof.

Abstract: A method of producing a high primary hydroxyl group content and a high number average molecular weight polyol includes preparing a mixture that includes a double metal cyanide catalyst and a low molecular weight polyether polyol having a number average molecular weight of less than 1,000 g/mol, the polyether polyol is derived from propylene oxide, ethylene oxide, or butylene oxide, setting the mixture to having a first temperature, adding at least one selected from propylene oxide, ethylene oxide, and butylene oxide to the mixture at the first temperature, allowing the mixture to react to form a reacted mixture, adding a Lewis acid catalyst to the reacted mixture, setting the reaction mixture including the second catalyst to have a second temperature that is less than the first temperature, and adding additional at least one selected from propylene oxide, ethylene oxide, and butylene oxide to the reacted mixture at the second temperature such that a resultant polyol having a primary hydroxyl group content of

Abstract: Sound-permeable lining (1) for covering perforations (21) shaped in an acoustic plasterboard (2). The sound-permeable lining (1) comprises a first ply (12) of a fleece material and attached thereto a second ply (14) which is arranged in between of the first ply (12) and the acoustic plasterboard (2) to which the sound-permeable lining (1) is to be applied. The second ply (14) being of a foil material having a second opacity O2 and a plurality of through-holes (141) formed therein. The first ply (12) has a first opacity O1 so that the through-holes (141) formed in the second ply (14) are invisible through the first ply (12) and so that the applied sound-permeable lining (1) has an overall opacity O12 to allow for optically covering the perforations (21) shaped in the acoustic plasterboard (2) and an overall air flow resistivity Rs12 to allow for the penetration of air so that sound can propagate via the sound-permeable lining (1).

Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

Abstract: {4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of AKI (acute kidney injury). Medicament and pharmaceutical composition thereof.

Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

Abstract: The invention therefore relates to compounds of the formula I in which A, X, Y, R1, R2 and R3 have the given meanings. The compounds of the formula I are suitable, for example, for wound healing.

Abstract: A method for the introduction of auxiliary grinding bodies into an agitator ball mill and for the removal of auxiliary grinding bodies from an agitator ball mill. The auxiliary grinding bodies are transported into the agitator ball mill and out of the latter via a closed circuit by means of a hydraulic conveying medium.

Abstract: Embodiments relate to determining a speed of a multidimensional motion of an athlete in a global coordinate system based on multidimensional acceleration data from a multidimensional accelerometer placed at a movable limb of the athlete, the movable limb being at least one of translatory and rotatable, and the movable limb defining a local coordinate system. Based on the multidimensional acceleration data, at least one correction quantity may be determined taking into account a rotation of the local coordinate system relative to the global coordinate system during the multidimensional motion. The speed of the multidimensional motion may be determined based on an integration of the multidimensional acceleration data and in consideration of the at least one correction quantity.

Abstract: The invention relates to oxazolopyrimidine compounds of formula I, where A, R1 and R2 are defined as stated in the claims. The compounds of formula I are suitable, for example, for wound healing.

Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

Abstract: Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring The invention therefore relates to compounds of the formula I in which X, Y, R1, R2 and R3 have the given meanings. The compounds of the formula I are suitable, for example, for wound healing.